Clinical trial NCT06020014: Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
Official title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Asthma
Keywords: asthma, Janus kinase inhibitor
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2023-08-31
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.


Eligibility criteria: Inclusion Criteria:

1. 18 to 80 years of age inclusive, at the time of signing the informed consent.
2. Treated with medium-high dose ICS in combination with LABA at a stable dose for at least 28 days prior to Visit 1.

   Note: EU participants must be treated with high dose ICS in combination with LABA at a stable dose for at least 28 days prior to V1.
3. Documented history of ≥ 1 severe asthma exacerbation within 1 year prior to Visit 1.
4. Morning pre-BD FEV1 ≥ 40% predicted at Visit 1 and Visit 3.
5. Able to perform acceptable lung function testing for FEV1 according to ATS/ERS 2019 acceptability criteria.
6. Documented evidence of asthma in the 10 years up to or including Visit 1. A clinical diagnosis of asthma must be documented at least 12 months prior to Screening (Visit 1).
7. An ACQ-6 score ≥ 1.5 at Visit 1 and at Visit 3.

9. Body weight of ≥ 40 kg and body mass index of \< 35 kg/m2. 10. Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. There are no restrictions on male participants or their female partners

At the end of the Run-in period (Visit 3), participants must fulfil the following additional criteria in order to be randomised into the study and enter the Treatment period:

1. Pre-BD FEV1 ≥ 40%.
2. A pre-BD/pre-IMP dose FEV1 at Visit 3 that has not increased or decreased by 20% or more from the pre-BD FEV1 recorded at Visit 1 and at Visit 2.
3. An ACQ-6 score of ≥ 1.5.
4. At least 80% compliance with usual asthma background medication during Run-in period (from Visit 2 to Visit 3) based on the daily asthma ePROs.
5. Minimum 80% compliance with daily eCOAs (electronic Clinical Outcome Assessments) during the 14 days preceding Visit 3.
6. For female of child bearing potential participants, a negative urine pregnancy test prior to administration of IMP.

Exclusion Criteria:

1. A severe asthma exacerbation within 8 weeks prior to randomisation.
2. History of herpes zoster reactivation.
3. Participants with a significant COVID-19 illness within 6 months of enrolment.
4. Clinically important pulmonary disease other than asthma.
5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

   * affect the safety of the participant throughout the study,
   * influence the findings of the study or the interpretation, or
   * impede the participant's ability to complete the entire duration of study.
6. Any clinically significant cardiac or cerebrovascular disease.
7. History of venous thromboembolism.
8. Participants who, as judged by the investigator, have evidence of active TB, or latent TB without completion of an appropriate course of treatment or appropriate ongoing prophylactic treatment.
9. Participants with a recent history of, or who have a positive test for, infective hepatitis or unexplained jaundice, or participants who have been treated for HIV.
10. Current or prior history of alcohol or drug abuse (including marijuana and marijuana containing valid prescriptions), as judged by the investigator.
11. History of malignancy other than superficial basal cell carcinoma.
12. Treatment with systemic corticosteroid within 4 weeks (oral) or 8 weeks (intramuscular) before Visit 1.
13. Any immunosuppressive therapy within 12 weeks prior to Visit 1.
14. Treatment with marketed biologics within 6 months of Visit 1 or 5 half-lives, whichever is longer.
15. Inhaled corticosteroid plus fast-acting β2 agonist as a reliever is not allowed 15 days prior to Visit 1, during Screening/Run-in and throughout the Treatment period and preferably 1 week after the last dose of IMP.
16. Live, attenuated, or mRNA vaccines within 4 weeks of Visit 1.
17. Immunoglobulin or blood products within 4 weeks of Visit 1.
18. Any immunotherapy within 6 months of Visit 1, except for stable maintenance dose allergen-specific immunotherapy started at least 4 weeks prior to Visit 1 and expected to continue through to the end of the Follow-up period.
19. Concurrent enrolment in another interventional clinical study
20. Participant treated with any investigational drug within 4 months or 5 half-lives, whichever is longer, prior to Visit 1.
21. Participants with a known hypersensitivity to AZD4604 or any of the excipients of the product.
22. Abnormal findings identified on physical examination, ECG, or laboratory testing.
23. For female participants only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
24. Current smokers or participants with smoking history ≥ 10 pack-years.
25. Participants with a known long-term exposure to occupational asbestos, silica, radon, heavy metals, and polycyclic aromatic hydrocarbons.
26. Positive family history of primary lung cancer in first degree relatives (mother, father, sisters, brothers and children).
27. Positive urine cotinine test or exhaled carbon monoxide test at Visit 1 and at any timepoint throughout the study.
28. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
29. Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
30. Donation of blood (≥ 450 mL) within 3 months or donation of plasma within 14 days before Visit 1.
31. Major surgery within 8 weeks prior to Visit 1, or planned inpatient surgery, major dental procedure or hospitalisation during Screening, Treatment, or Follow-up periods.

Primary outcomes:
measure: Time to first CompEx Asthma event
timeFrame: 12 weeks
Secondary outcomes:
measure: Pre-BD FEV1
timeFrame: 12 weeks
measure: CAAT
timeFrame: 12 weeks
measure: ACQ-6
timeFrame: 12 weeks
measure: Average morning and average evening PEF
timeFrame: 12 weeks
measure: Daily asthma symptom score (total, daytime, and night-time)
timeFrame: 12 weeks
measure: Time to first CompEx acute worsening event
timeFrame: 12 weeks
measure: CompEx event rate
timeFrame: 12 weeks
measure: CompEx acute worsening event rate
timeFrame: 12 weeks
measure: FeNO
timeFrame: 12 weeks
measure: Cough
timeFrame: 12 weeks
measure: PK
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Research Site
state: Alabama
city: Chandler
country: United States
facility: Research Site
state: Arizona
city: La Jolla
country: United States
facility: Research Site
state: California
city: Newport Beach
country: United States
facility: Research Site
state: California
city: North Hollywood
country: United States
facility: Research Site
state: California
city: Sacramento
country: United States
facility: Research Site
state: California
city: Stockton
country: United States
facility: Research Site
state: California
city: Denver
country: United States
facility: Research Site
state: Colorado
city: Lakewood
country: United States
facility: Research Site
state: Colorado
city: Lakeland
country: United States
facility: Research Site
state: Florida
city: Miami
country: United States
facility: Research Site
state: Florida
city: Miami
country: United States
facility: Research Site
state: Florida
city: Tallahassee
country: United States
facility: Research Site
state: Florida
city: Atlanta
country: United States
facility: Research Site
state: Georgia
city: Hammond
country: United States
facility: Research Site
state: Indiana
city: New Bedford
country: United States
facility: Research Site
state: Massachusetts
city: Ann Arbor
country: United States
facility: Research Site
state: Michigan
city: Southfield
country: United States
facility: Research Site
state: Michigan
city: Saint Charles
country: United States
facility: Research Site
state: Missouri
city: Las Vegas
country: United States
facility: Research Site
state: Nevada
city: Union City
country: United States
facility: Research Site
state: New Jersey
city: Asheville
country: United States
facility: Research Site
state: North Carolina
city: Charlotte
country: United States
facility: Research Site
state: North Carolina
city: New Bern
country: United States
facility: Research Site
state: North Carolina
city: Salisbury
country: United States
facility: Research Site
state: North Carolina
city: Winston-Salem
country: United States
facility: Research Site
state: North Carolina
city: Columbus
country: United States
facility: Research Site
state: Ohio
city: Boerne
country: United States
facility: Research Site
state: Texas
city: El Paso
country: United States
facility: Research Site
state: Texas
city: Houston
country: United States
facility: Research Site
state: Texas
city: Madison
country: United States
facility: Research Site
state: Wisconsin
city: Buenos Aires
country: Argentina
facility: Research Site
city: Buenos Aires
country: Argentina
facility: Research Site
city: Buenos Aires
country: Argentina
facility: Research Site
city: Ciudad de Buenos Aires
country: Argentina
facility: Research Site
city: Florida
country: Argentina
facility: Research Site
city: La Plata
country: Argentina
facility: Research Site
city: Ranelagh
country: Argentina
facility: Research Site
city: Barretos
country: Brazil
facility: Research Site
city: Blumenau
country: Brazil
facility: Research Site
city: Brasilia
country: Brazil
facility: Research Site
city: Campinas
country: Brazil
facility: Research Site
city: Campinas
country: Brazil
facility: Research Site
city: Porto Alegre
country: Brazil
facility: Research Site
city: Porto Alegre
country: Brazil
facility: Research Site
city: Sao Bernardo do Campo
country: Brazil
facility: Research Site
city: Sao Bernardo do Campo
country: Brazil
facility: Research Site
city: Sao Jose Do Rio Preto
country: Brazil
facility: Research Site
city: Burgas
country: Bulgaria
facility: Research Site
city: Pazardzhik
country: Bulgaria
facility: Research Site
city: Pleven
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Varna
country: Bulgaria
facility: Research Site
city: Aarhus
country: Denmark
facility: Research Site
city: Hellerup
country: Denmark
facility: Research Site
city: Hvidovre
country: Denmark
facility: Research Site
city: København NV
country: Denmark
facility: Research Site
city: København Ø
country: Denmark
facility: Research Site
city: Næstv
country: Denmark
facility: Research Site
city: Odense C
country: Denmark
facility: Research Site
city: Vejle
country: Denmark
facility: Research Site
city: Ålborg
country: Denmark
facility: Research Site
city: Antony
country: France
facility: Research Site
city: Cannes
country: France
facility: Research Site
city: Epagny Metz-Tessy
country: France
facility: Research Site
city: Libourne Cedex
country: France
facility: Research Site
city: Lyon Cedex 04
country: France
facility: Research Site
city: Montpellier
country: France
facility: Research Site
city: Quimper
country: France
facility: Research Site
city: Strasbourg
country: France
facility: Research Site
city: VANNES cedex
country: France
facility: Research Site
city: Berlin
country: Germany
facility: Research Site
city: Berlin
country: Germany
facility: Research Site
city: Berlin
country: Germany
facility: Research Site
city: Berlin
country: Germany
facility: Research Site
city: Cottbus
country: Germany
facility: Research Site
city: Darmstadt
country: Germany
facility: Research Site
city: Frankfurt am Main
country: Germany
facility: Research Site
city: Koblenz
country: Germany
facility: Research Site
city: Mainz
country: Germany
facility: Research Site
city: München
country: Germany
facility: Research Site
city: Peine
country: Germany
facility: Research Site
city: Schwerin
country: Germany
facility: Research Site
city: Ajmer
country: India
facility: Research Site
city: Belagavi
country: India
facility: Research Site
city: Coimbatore
country: India
facility: Research Site
city: Hyderabad
country: India
facility: Research Site
city: Kolkata
country: India
facility: Research Site
city: Kozhikode
country: India
facility: Research Site
city: New Delhi
country: India
facility: Research Site
city: Daegu
country: Korea, Republic of
facility: Research Site
city: Daegu
country: Korea, Republic of
facility: Research Site
city: Gyeonggi-do
country: Korea, Republic of
facility: Research Site
city: Incheon
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Suwon-si
country: Korea, Republic of
facility: Research Site
city: Batu Caves
country: Malaysia
facility: Research Site
city: Kajang
country: Malaysia
facility: Research Site
city: Kota Bharu
country: Malaysia
facility: Research Site
city: Kuala Lumpur
country: Malaysia
facility: Research Site
city: Kuantan
country: Malaysia
facility: Research Site
city: Melaka
country: Malaysia
facility: Research Site
city: Sarawak Miri
country: Malaysia
facility: Research Site
city: Sungai Buloh
country: Malaysia
facility: Research Site
city: Dagupan City
country: Philippines
facility: Research Site
city: Davao City
country: Philippines
facility: Research Site
city: Mabalacat
country: Philippines
facility: Research Site
city: Manadaluyong City
country: Philippines
facility: Research Site
city: Quezon City
country: Philippines
facility: Research Site
city: Roxas City
country: Philippines
facility: Research Site
city: Cape Town
country: South Africa
facility: Research Site
city: Durban
country: South Africa
facility: Research Site
city: Durban
country: South Africa
facility: Research Site
city: Newton
country: South Africa
facility: Research Site
city: Observatory
country: South Africa
facility: Research Site
city: Umkomaas
country: South Africa
facility: Research Site
city: Barcelona
country: Spain
facility: Research Site
city: Granada
country: Spain
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Majadahonda
country: Spain
facility: Research Site
city: Marbella
country: Spain
facility: Research Site
city: Palma de Mallorca
country: Spain
facility: Research Site
city: Santiago de Compostela
country: Spain
facility: Research Site
city: Linköping
country: Sweden
facility: Research Site
city: Lund
country: Sweden
facility: Research Site
city: Stockholm
country: Sweden
facility: Research Site
city: Stockholm
country: Sweden
facility: Research Site
city: Umeå
country: Sweden
facility: Research Site
city: Örebro
country: Sweden
facility: Research Site
city: Kaohsiung
country: Taiwan
facility: Research Site
city: Taichung
country: Taiwan
facility: Research Site
city: Taipei City
country: Taiwan
facility: Research Site
city: Taipei City
country: Taiwan
facility: Research Site
city: Taipei
country: Taiwan
facility: Research Site
city: Taipei
country: Taiwan
facility: Research Site
city: Taipei
country: Taiwan
facility: Research Site
city: Taoyuan City
country: Taiwan
facility: Research Site
city: Yunlin
country: Taiwan
facility: Research Site
city: Bangkok
country: Thailand
facility: Research Site
city: Chiang Mai
country: Thailand
facility: Research Site
city: Hat Yai
country: Thailand
facility: Research Site
city: Khlong Luang
country: Thailand
facility: Research Site
city: Khon Kaen
country: Thailand
facility: Research Site
city: Birmingham
country: United Kingdom
facility: Research Site
city: Bradford
country: United Kingdom
facility: Research Site
city: Chesterfield
country: United Kingdom
facility: Research Site
city: Leeds
country: United Kingdom
facility: Research Site
city: Liverpool
country: United Kingdom
facility: Research Site
city: London
country: United Kingdom
facility: Research Site
city: Penzance
country: United Kingdom
facility: Research Site
city: Thetford
country: United Kingdom
facility: Research Site
city: Wellingborough
country: United Kingdom
facility: Research Site
city: Da Nang
country: Vietnam
facility: Research Site
city: Ha Noi
country: Vietnam
facility: Research Site
city: Hanoi
country: Vietnam
facility: Research Site
city: Ho Chi Minh city
country: Vietnam
facility: Research Site
city: Ho Chi Minh
country: Vietnam
facility: Research Site
city: Ho Chi Minh
country: Vietnam
facility: Research Site
city: Hochiminh
country: Vietnam
facility: Research Site
city: Hue
country: Vietnam
facility: Research Site
Study officials:
References: